'Skinny jabs': weight-loss drugs set for new boom as generic versions emerge
Medicines like Wegovy and Saxenda, known as "skinny jabs," are gaining popularity for weight loss. Generic versions, like Teva's generic Victoza, are expected to increase accessibility and affordability, benefiting a broader population. Novo Nordisk invests $4 billion to meet rising demand.
Read original article
Medicines enabling significant weight loss, known as "skinny jabs," are expected to see increased demand with the introduction of generic versions at lower costs. Popular drugs like Wegovy and Saxenda, along with Ozempic and Victoza, are gaining traction for their weight-loss benefits. Novo Nordisk, the maker of Ozempic, is investing $4 billion to meet the rising demand for these injections in the US. The availability of generic versions, such as Teva's generic Victoza, is set to make these treatments more accessible globally. The move towards generics is anticipated to reduce prices significantly, making these medications more affordable for patients, including those under the NHS. Experts believe that increased competition and the availability of generic versions will lead to a broader population benefiting from these weight-loss treatments, potentially transforming public health outcomes.
Related
Study identifies first drug therapy for sleep apnea
Researchers at UC San Diego found tirzepatide, a diabetes drug, promising for treating sleep apnea. The study on 469 participants worldwide showed reduced breathing interruptions, weight loss, and improved heart health. Tirzepatide may offer a new OSA treatment option.
Next-generation psychedelics: should new agents skip the trip?
Companies are investing in next-generation psychedelics to enhance mental health treatment, focusing on reducing psychoactive effects while maintaining therapeutic benefits. Despite expanding interest and investments, questions persist about efficacy and cost-effectiveness.
A 5,2 Intermittent Fasting Meal Replacement Diet for Adults with Diabetes
A randomized trial compared 5:2 intermittent fasting with metformin and empagliflozin in diabetic adults. Results showed improved glycemic control with reduced HbA1c levels and fasting glucose, suggesting potential benefits for diabetes management.
Hims & Hers Selling GLP-1 Injection That’s Not FDA Approved, From Shady Supplier
Hims & Hers sells non-FDA approved weight loss drug through loophole, raising concerns about patient safety, legality, and supplier's history of fraud. Executives sold shares amid risks of legal consequences.
Pharma firms stash profits in Europe's tax havens
Pharma firms hide €580 billion in European tax havens, affecting drug prices and patient access. Companies exploit tax loopholes, impacting healthcare funding. Calls for transparency and accountability in the pharmaceutical industry arise.
3 commentsRelated
Study identifies first drug therapy for sleep apnea
Researchers at UC San Diego found tirzepatide, a diabetes drug, promising for treating sleep apnea. The study on 469 participants worldwide showed reduced breathing interruptions, weight loss, and improved heart health. Tirzepatide may offer a new OSA treatment option.
Next-generation psychedelics: should new agents skip the trip?
Companies are investing in next-generation psychedelics to enhance mental health treatment, focusing on reducing psychoactive effects while maintaining therapeutic benefits. Despite expanding interest and investments, questions persist about efficacy and cost-effectiveness.
A 5,2 Intermittent Fasting Meal Replacement Diet for Adults with Diabetes
A randomized trial compared 5:2 intermittent fasting with metformin and empagliflozin in diabetic adults. Results showed improved glycemic control with reduced HbA1c levels and fasting glucose, suggesting potential benefits for diabetes management.
Hims & Hers Selling GLP-1 Injection That’s Not FDA Approved, From Shady Supplier
Hims & Hers sells non-FDA approved weight loss drug through loophole, raising concerns about patient safety, legality, and supplier's history of fraud. Executives sold shares amid risks of legal consequences.
Pharma firms stash profits in Europe's tax havens
Pharma firms hide €580 billion in European tax havens, affecting drug prices and patient access. Companies exploit tax loopholes, impacting healthcare funding. Calls for transparency and accountability in the pharmaceutical industry arise.